LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Search

TG Therapeutics Inc

Chiusa

SettoreSettore sanitario

31.39 -1.29

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

31.27

Massimo

31.77

Metriche Chiave

By Trading Economics

Entrata

363M

391M

Vendite

21M

162M

P/E

Media del settore

11.13

77.671

Margine di Profitto

241.727

Dipendenti

374

EBITDA

-4.9M

33M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+43.54% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-451M

4.9B

Apertura precedente

32.68

Chiusura precedente

31.39

Notizie sul Sentiment di mercato

By Acuity

50%

50%

167 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

TG Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 dic 2025, 16:42 UTC

Acquisizioni, Fusioni, Takeovers

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

12 dic 2025, 23:49 UTC

Acquisizioni, Fusioni, Takeovers

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 dic 2025, 22:52 UTC

Discorsi di Mercato

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 dic 2025, 22:32 UTC

Utili

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

12 dic 2025, 20:45 UTC

Utili

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 dic 2025, 20:41 UTC

Discorsi di Mercato

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 dic 2025, 20:20 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 dic 2025, 19:23 UTC

Utili

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 dic 2025, 18:35 UTC

Acquisizioni, Fusioni, Takeovers

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 dic 2025, 18:33 UTC

Acquisizioni, Fusioni, Takeovers

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 dic 2025, 18:31 UTC

Discorsi di Mercato

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 dic 2025, 17:49 UTC

Utili

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 dic 2025, 17:34 UTC

Acquisizioni, Fusioni, Takeovers

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

12 dic 2025, 17:33 UTC

Acquisizioni, Fusioni, Takeovers

Orange: Closing of the Transaction Is Expected in the First Half of 2026

12 dic 2025, 17:33 UTC

Acquisizioni, Fusioni, Takeovers

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

12 dic 2025, 17:32 UTC

Acquisizioni, Fusioni, Takeovers

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

12 dic 2025, 17:31 UTC

Acquisizioni, Fusioni, Takeovers

Orange to Buy the Stake for EU4.25B in Cash

12 dic 2025, 17:24 UTC

Discorsi di Mercato

Argentina Predicts Record Wheat Crop -- Market Talk

12 dic 2025, 17:20 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

12 dic 2025, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

12 dic 2025, 17:18 UTC

Discorsi di Mercato
Utili

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

12 dic 2025, 17:09 UTC

Discorsi di Mercato

Broadcom Investors Were Primed to Sell Shares -- Market Talk

12 dic 2025, 17:09 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

12 dic 2025, 16:47 UTC

Discorsi di Mercato

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

12 dic 2025, 16:39 UTC

Discorsi di Mercato

Supply Limits, Geopolitical Risk to Support Crude in 2026 -- Market Talk

12 dic 2025, 16:27 UTC

Acquisizioni, Fusioni, Takeovers

FTC Sues to Block Henkel's $725M Deal for Liquid Nails From PE Firm -- 2nd Update

12 dic 2025, 16:15 UTC

Utili

At Costco, Lots of Pie but No Special Dividend. Why the Street Didn't Like the Earnings. -- Barrons.com

12 dic 2025, 15:35 UTC

Utili

These Stocks Are Moving the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dic 2025, 14:46 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

TG Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

43.54% in crescita

Previsioni per 12 mesi

Media 45 USD  43.54%

Alto 60 USD

Basso 11 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per TG Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

4

Acquista

0

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

N/A / 34.86Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

167 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat